Tilavonemab Not Effective in Progressive Supranuclear Palsy
Researchers assessed the safety and efficacy of tilavonemab for treating progressive supranuclear palsy, a neurodegenerative disorder linked to tau protein aggregation.
Progressive Supranuclear Palsy
Novel Therapy for Progressive Supranuclear Palsy Gets Orphan Drug Designation
The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP).
Atypical Parkinsonian Disorders: Reviewing the Complex Web of Proteinopathies
While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.
New Clinical Guidelines: Distinguishing Variations of Progressive Supranuclear Palsy
New guidelines for progressive supranuclear palsy provide very specific and sensitive criteria that allow for identification of clinical features of the disease at much earlier stages.
- Loading...
Loading...
Next post in Movement Disorders
Loading... 
Loading...